For instance, prostate specific membrane antigen (PSMA), which is upregulated in many metastatic prostate tumors, can be targeted with its radiolabeled inhibitor and used for imaging modalities or radiotherapy (129, 130). This evidence concerns the gene FOLH1 and prostate neoplasm.